BioWorld MedTech

Feb. 23, 2015

View Archived Issues

PwC report points out change in industry/FDA relationship

Inside the Beltway: Litwack says biggest concern for NGS is specific intended use

Financings: Saluda gets $10 million in new B round for chronic pain research

MDD Stock Report winners and losers

MDD Stock Report for Public Med-tech Companies

23andMe wins DTC approval for Bloom Syndrome genetic test

HIT Bits HIT Bits: Resolute H:ealth Hospital achieves HIMSS Analytics Stage 6 status

Restructuring: Integra Lifesciences cut 49 positions in Massachusetts facility late last year

Products

People in Places

MDD's Neurology Extra

Medtronic publishes five-year results from SANTE trial for DBS in epilepsy

Five-year results from a clinical study evaluating the use of deep brain stimulation (DBS) in adult epilepsy patients supports the use of DBS for treatment-resistant (refractory) epilepsy. Read More

Perspectives Blog: Dam it: CMS plays the part of Hoover

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...